Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

University of Bristol

Roche acquires digital diabetes management platform

Will integrate mySugr within its new patient-centred health services arm

- PMLiVE

FDA panel backs CV claims for Novo Nordisk’s Victoza

LEADER trial shows the diabetes treatment reduces risk of cardiovascular death by 13%

- PMLiVE

Trial of J&J’s canagliflozin boosts SGLT2 cardiovascular credentials

Invokana cuts risk of heart failure hospitalisation by a third

- PMLiVE

Novo says real-world data backs its insulin switching

EU-TREAT study shows Tresiba improved blood glucose control

Research Partnership launches new patient Living With Non-alcoholic Steatohepatitis (NASH) report

Living with Non-alcoholic Steatohepatitis (NASH) is a study conducted amongst 100 adults with NASH in the US. The study employs a mixed quantitative/qualitative methodology and will be available to purchase...

Research Partnership

- PMLiVE

Novo seeks to strengthen Tresiba label in US

Studies find insulin degludec advantage over insulin glargine

- PMLiVE

Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog

Panel recommends insulin Lispro Sanofi to treat diabetes

Sanofi reception

Sanofi agrees €250m diabetes deal with AI firm Exscientia

The French pharma giant will pay royalties and contribute research funding

Eli Lilly HQ

Surging Trulicity takes sting out of Lilly’s arthritis setback

First quarter sales of the diabetes treatment were up by 160%, exceeding analysts predictions

- PMLiVE

FDA won’t add outcomes data to Januvia label

Merck & Co’s application rejected despite TECOS outcomes data

AstraZeneca AZ

AZ data suggest SGLT2 inhibitors can reduce heart failure risk

Publishes real-world data for study involving Forxiga/Farxiga, Invokana and Jardiance

Sanofi to develop a mobile app for insulin patients

Will work with therapeutic companion software company Voluntis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links